Pronota, a Belgian developer of diagnostics for early detection of life-threatening conditions, has appointed Carol Greve-Philips as chief business officer and Els Hubloux as chief financial officer.
Greve-Philips is an experienced biotechnology professional with more than 20 years of business development skills. She joins Pronota from Genzyme, where she was vice president of corporate development, responsible for building collaborations with industry partners.
In addition, Greve-Phillips led successful out-licensing transactions for non-core assets. She has also held roles in direct sales, sales management and marketing for Amersham Corporation, Chemsyn Science Laboratories, Watson Laboratories and Toxikon Corporation.
Els Hubloux
Hubloux joins Pronota from Capricorn Venture Partners. Her career encompasses more than 16 years of experience in clinical research and development, equity research and venture capital investment.
